Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
allogeneic blood cells (1 trial)
azacitidine (vidaza) (1 trial)
bone marrow derived mesenchymal stem cells (1 trial)
busulfan (Myleran) (3 trials)
cyclophosphamide (cytoxan) (3 trials)
decitabine (dacogen) (3 trials)
Filgrastim (neupogen) (3 trials)
fludarabine (fludara) (3 trials)
Homoharringtonine (1 trial)
sorafenib (nexavar) (1 trial)
venetoclax (venclexta) (1 trial)
sailuotong (1 trial)
etanercept (enbrel) (1 trial)
ketamine (ketalar) (1 trial)
Acute Disease (Phase 3)
Dementia (Phase 2)
Dementia, Vascular (Phase 2)
Leukemia (Phase 3)
Recurrence (Phase 3)
Trials (9 total)
Trial APIs (14 total)